Related Experiment Video
Updated: Jun 29, 2025
Isolation and Characterization of the Murine Uterosacral Ligaments and Pelvic Floor Organs
Published on: March 3, 2023
Targeting the relaxin-3/RXFP3 system: a patent review for the last two decades
Md Toufiqur Rahman1, Hetti Handi Chaminda Lakmal1, Javeena Hussain1
1Center for Drug Discovery, Research Triangle Institute, Research Triangle Park, NC, USA.
Introduction:
The neuropeptide relaxin-3/RXFP3 system belongs to the relaxin/insulin superfamily and is involved in many important physiological processes, such as stress responses, appetite control, and motivation for reward. Although relaxin-3 is the endogenous agonist for RXFP3, it can also bind to and activate RXFP1 and RXFP4. Consequently, research has been focused on the development of RXFP3-specific peptides and small-molecule ligands to validate the relaxin-3/RXFP3 system as a novel drug target.
Areas Covered:
This review provides an overview of patents on the relaxin-3/RXFP3 system covering ligand development and pharmacological studies since 2003. Related patents and literature reports were obtained from established sources including SciFinder, Google Patents, and Espacenet for patents and SciFinder, PubMed, and Google Scholar for literature reports.
Expert Opinion:
There has been an increasing amount of patent activities around relaxin-3/RXFP3, highlighting the importance of this novel neuropeptide system for drug discovery. The development of relaxin-3 derived peptides and small-molecule modulators, as well as behavioral studies in rodents, have shown that the relaxin-3/RXFP3 system is a promising drug target for treating various metabolic and neuropsychiatric diseases including obesity, anxiety, and alcohol addiction.
